Literature DB >> 17805311

Drugs of abuse specifically sensitize noradrenergic and serotonergic neurons via a non-dopaminergic mechanism.

Christophe Lanteri1, Lucas Salomon, Yvette Torrens, Jacques Glowinski, Jean-Pol Tassin.   

Abstract

A challenge in drug dependence is to delineate long-term neurochemical modifications induced by drugs of abuse. Repeated d-amphetamine was recently shown to disrupt a mutual regulatory link between noradrenergic and serotonergic neurons, thus inducing long-term increased responses to d-amphetamine and para-chloroamphetamine, respectively. We show here that such a sensitization of noradrenergic and serotonergic neurons also occurs following repeated treatment with cocaine, morphine, or alcohol, three compounds belonging to main groups of addictive substances. In all cases, this sensitization is prevented by alpha 1b-adrenergic and 5-HT2A receptors blockade, indicating the critical role of these receptors on long-term effects of drugs of abuse. However, repeated treatments with two non-addictive antidepressants, venlafaxine, and clorimipramine, which nevertheless inhibit noradrenergic and serotonergic reuptake, do not induce noradrenergic and serotonergic neurons sensitization. Similarly, this sensitization does not occur following repeated treatments with a specific inhibitor of dopamine (DA) reuptake, GBR12783. Moreover, we show that the effects of SCH23390, a D1 receptor antagonist known to inhibit development of d-amphetamine behavioral sensitization, are due to its 5-HT2C receptor agonist property. SCH23390 blocks amphetamine-induced release of norepinephrine and RS102221, a 5-HT2C antagonist, can reverse this inhibition as well as inhibition of noradrenergic sensitization and development of behavioral sensitization induced by repeated d-amphetamine. We propose that noradrenergic/serotonergic uncoupling is a common neurochemical consequence of repeated consumption of drugs of abuse, unrelated with DA release. Our data also suggest that compounds able to restore the link between noradrenergic and serotonergic modulatory systems could represent important therapeutic targets for investigation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17805311     DOI: 10.1038/sj.npp.1301548

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  33 in total

1.  Involvement of noradrenergic neurotransmission in the stress- but not cocaine-induced reinstatement of extinguished cocaine-induced conditioned place preference in mice: role for β-2 adrenergic receptors.

Authors:  John R Mantsch; Andy Weyer; Oliver Vranjkovic; Chad E Beyer; David A Baker; Holly Caretta
Journal:  Neuropsychopharmacology       Date:  2010-07-07       Impact factor: 7.853

2.  Amphetamine modifies ethanol intake of psychosocially stressed male rats.

Authors:  Larissa A Pohorecky; April Sweeny
Journal:  Pharmacol Biochem Behav       Date:  2012-01-20       Impact factor: 3.533

3.  Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion.

Authors:  Jermaine D Jones; F Scott Hall; George R Uhl; Kenner Rice; Anthony L Riley
Journal:  Pharmacol Biochem Behav       Date:  2009-04-17       Impact factor: 3.533

4.  Adolescent social isolation increases anxiety-like behavior and ethanol intake and impairs fear extinction in adulthood: Possible role of disrupted noradrenergic signaling.

Authors:  M J Skelly; A E Chappell; E Carter; J L Weiner
Journal:  Neuropharmacology       Date:  2015-06-01       Impact factor: 5.250

5.  Effects of β-adrenoceptor antagonists on alcohol drinking by alcohol-dependent rats.

Authors:  Nicholas W Gilpin; George F Koob
Journal:  Psychopharmacology (Berl)       Date:  2010-07-31       Impact factor: 4.530

6.  Reversal of long-term methamphetamine sensitization by combination of pergolide with ondansetron or ketanserin, but not mirtazapine.

Authors:  Kamal S Bhatia; Steven T Szabo; J Corey Fowler; William C Wetsel; Tong H Lee
Journal:  Behav Brain Res       Date:  2011-05-07       Impact factor: 3.332

7.  Doxazosin for the treatment of co-occurring PTSD and alcohol use disorder: Design and methodology of a randomized controlled trial in military veterans.

Authors:  Sudie E Back; Julianne C Flanagan; Jennifer L Jones; Isabel Augur; Alan L Peterson; Stacey Young-McCaughan; David W Shirley; Aisling Henschel; Jane E Joseph; Brett T Litz; Allison K Hancock; John D Roache; Jim Mintz; Jennifer S Wachen; Terence M Keane; Kathleen T Brady
Journal:  Contemp Clin Trials       Date:  2018-08-24       Impact factor: 2.226

8.  alpha1-noradrenergic receptor antagonism blocks dependence-induced increases in responding for ethanol.

Authors:  Brendan M Walker; Dennis D Rasmussen; Murray A Raskind; George F Koob
Journal:  Alcohol       Date:  2008-03       Impact factor: 2.405

9.  Preclinical evaluation of the abuse potential of the analgesic bicifadine.

Authors:  Katherine L Nicholson; Robert L Balster; Krystyna Golembiowska; Magdalena Kowalska; Joseph P Tizzano; Phil Skolnick; Anthony S Basile
Journal:  J Pharmacol Exp Ther       Date:  2009-04-08       Impact factor: 4.030

10.  Voluntary exercise or amphetamine treatment, but not the combination, increases hippocampal brain-derived neurotrophic factor and synapsin I following cortical contusion injury in rats.

Authors:  G S Griesbach; D A Hovda; F Gomez-Pinilla; R L Sutton
Journal:  Neuroscience       Date:  2008-04-09       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.